Last update 07 Jan 2025
SYH2053
Last update 07 Jan 2025
Overview
Basic Info
Drug Type siRNA |
Synonyms SYH2053 |
Target |
Mechanism PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with SYH2053A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein Cholesterol
一项单中心、随机、双盲、安慰剂对照、单次剂量递增、评价SYH2053注射液在中国低密度脂蛋白胆固醇正常或升高参与者中的安全性、耐受性、药代动力学和药效学特征的Ⅰ期临床试验
[Translation] A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SYH2053 injection in Chinese participants with normal or elevated low-density lipoprotein cholesterol
一项多中心、随机、双盲、安慰剂及阳性药对照，评价在背景治疗的基础上不同剂量SYH2053注射液对中国原发性高胆固醇血症或混合血脂异常参与者的疗效、安全性的Ⅱ期研究
[Translation] A multicenter, randomized, double-blind, placebo- and active drug-controlled Phase II study to evaluate the efficacy and safety of different doses of SYH2053 injection on the basis of background treatment in Chinese participants with primary hypercholesterolemia or mixed dyslipidemia
100 Clinical Results associated with SYH2053
Login to view more data
100 Translational Medicine associated with SYH2053
Login to view more data
100 Patents (Medical) associated with SYH2053
Login to view more data
100 Deals associated with SYH2053
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Combined hyperlipidemia | Phase 2 | CN | 18 Nov 2024 | |
| Combined hyperlipidemia | Phase 2 | CN | 18 Nov 2024 | |
| Primary hypercholesterolemia | Phase 2 | CN | 18 Nov 2024 | |
| Primary hypercholesterolemia | Phase 2 | CN | 18 Nov 2024 | |
| Hyperlipidemia, Familial Combined | Phase 1 | CN | 08 Jan 2024 | |
| Hyperlipidemia, Familial Combined | Phase 1 | CN | 08 Jan 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free